《2025中国医药CRO企业20强》隆重发布

药智网
25 Jun

近年来,CRO行业面临着多重挑战与机遇。一方面,地缘政治紧张局势不断升级,如美国《生物安全法案》等相关政策的提出,使得全球医药CRO企业的跨境合作、数据安全和知识产权保护等面临更严格审查监管,部分跨国CRO公司运营受限。同时,全球经济不稳定致医药投融资遇冷,市场需求萎缩,致使CRO企业订单量价齐跌,部分企业生存艰难,甚至面临停业风险,陷入“死亡之谷”。困境之中,总有一些企业不断披荆斩棘、破浪前行。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10